Literature DB >> 31451300

Stiripentol for the treatment of primary hyperoxaluria and calcium oxalate nephropathy.

Christina M Wyatt1, Tilman B Drüeke2.   

Abstract

Entities:  

Keywords:  hyperoxaluria; uremic toxins

Year:  2019        PMID： 31451300     DOI： 10.1016/j.kint.2019.06.011

Source DB:  PubMed          Journal:  Kidney Int        ISSN： 0085-2538            Impact factor:   10.612


× No keyword cloud information.
  6 in total

1.  Protective effects of interleukin-22 on oxalate-induced crystalline renal injury via alleviating mitochondrial damage and inflammatory response.

Authors:  Yuting Gu; Yilan Shen; Wei Chen; Haidong He; Yulei Ma; Xiaobin Mei; Dianwen Ju; Hongrui Liu
Journal:  Appl Microbiol Biotechnol       Date:  2022-03-16       Impact factor: 4.813

Review 2.  New therapeutics for primary hyperoxaluria type 1.

Authors:  Pegah Dejban; John C Lieske
Journal:  Curr Opin Nephrol Hypertens       Date:  2022-03-09       Impact factor: 3.416

Review 3.  Primary hyperoxaluria type 1 in developing countries: novel challenges in a new therapeutic era.

Authors:  Neveen A Soliman; Sameh Mabrouk
Journal:  Clin Kidney J       Date:  2022-05-17

Review 4.  The Crystalline Nephropathies.

Authors:  Mark A Perazella; Leal C Herlitz
Journal:  Kidney Int Rep       Date:  2021-09-17

Review 5.  Treatment of primary hyperoxaluria type 1.

Authors:  Asheeta Gupta; Michael J G Somers; Michelle A Baum
Journal:  Clin Kidney J       Date:  2022-05-17

Review 6.  Future treatments for hyperoxaluria.

Authors:  Zachary Burns; John Knight; Sonia Fargue; Ross Holmes; Dean Assimos; Kyle Wood
Journal:  Curr Opin Urol       Date:  2020-03       Impact factor: 2.808
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.